HK Stock Market Move | Gold stocks generally fell back, ZIJIN GOLD INTL (02259) fell nearly 4%, LINGBAO GOLD (03330) fell nearly 3%.
Gold stocks have generally retreated, with Zijin Mining International (02259) falling by 3.93% to HK$219.8 at the time of writing; Lingbao Gold (03330) fell by 2.92% to HK$24.56.
Gold stocks are generally falling. As of press time, ZIJIN GOLD INTL (02259) fell by 3.93% to 219.8 Hong Kong dollars; LINGBAO GOLD (03330) fell by 2.92% to 24.56 Hong Kong dollars; CHINAGOLDINTL (02099) fell by 1.79% to 197.4 Hong Kong dollars; Chifeng Jilong Gold Mining (06693) fell by 1.32% to 37.26 Hong Kong dollars.
On the news front, the US non-farm payrolls added 130,000 in January, far exceeding market expectations, leading to a decrease in market interest rate expectations and a rapid rebound in the US dollar index. CITIC Futures believes that without clear signs of weakening employment and wages, it is difficult to interpret interest rate reduction trades unilaterally, and gold prices may enter a high-level volatility and emotional fluctuation stage. The medium-term direction still depends on changes in real interest rates and the trend of the US dollar. Baicheng Futures stated that as the Chinese New Year holiday approaches, funds are becoming more cautious. Key points for precious metals during the Chinese New Year holiday: On the geopolitical front, tensions between the US and Iran are still high, and any changes in their relationship may drive gold prices higher during the Chinese New Year holiday; in terms of US policies, market fluctuations may occur in the evaluation of potential candidates for the Chair of the Federal Reserve, so it is important to pay attention to the movements of Kevin Warsh.
Related Articles

Xinhua Lande (08106) plans to issue 9.835 million shares for private investment from Guangdong, Hong Kong, and Macau. Trading will resume on February 13.

KINTOR PHARMA-B (09939) will use cash flow from its cosmetics business to provide funding for medical/biological applications and development.

HENLIUS (02696) obtained NMPA approval for the Phase 1 clinical trial application of the HLX15-SC developed for the treatment of multiple myeloma.
Xinhua Lande (08106) plans to issue 9.835 million shares for private investment from Guangdong, Hong Kong, and Macau. Trading will resume on February 13.

KINTOR PHARMA-B (09939) will use cash flow from its cosmetics business to provide funding for medical/biological applications and development.

HENLIUS (02696) obtained NMPA approval for the Phase 1 clinical trial application of the HLX15-SC developed for the treatment of multiple myeloma.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


